Reunion Neuroscience Inc.

NasdaqGS:REUN Stock Report

Market Cap: US$12.5m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Reunion Neuroscience Past Earnings Performance

Past criteria checks 0/6

Reunion Neuroscience's earnings have been declining at an average annual rate of -68.5%, while the Biotechs industry saw earnings growing at 17.4% annually. Revenues have been growing at an average rate of 83.9% per year.

Key information

-68.5%

Earnings growth rate

-4.6%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate83.9%
Return on equity-178.9%
Net Marginn/a
Last Earnings Update31 Mar 2023

Recent past performance updates

Recent updates

Reunion Neuroscience announces resignation of director, general counsel

Oct 07

Reunion Neuroscience appoints Greg Mayes as President and CEO

Sep 28

Field Trip Health  GAAP EPS of -C$0.09

Aug 15

Field Trip Health receives final court approval for clinics business spin-out

Jun 29

Revenue & Expenses Breakdown

How Reunion Neuroscience makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGS:REUN Revenue, expenses and earnings (CAD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 230-381313
31 Dec 225-743911
30 Sep 225-68409
30 Jun 225-57399
31 Mar 220-18117
31 Dec 211-20136
30 Sep 211-22135
30 Jun 211-24134
31 Mar 211-23134
31 Dec 200-1693
30 Sep 200-962
30 Jun 200-541
31 Mar 200-330

Quality Earnings: REUN is currently unprofitable.

Growing Profit Margin: REUN is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if REUN's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare REUN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: REUN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-42.7%).


Return on Equity

High ROE: REUN has a negative Return on Equity (-178.92%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies